These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 19497323

  • 1. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X, Xu L, Yu J, Fang X.
    Exp Cell Res; 2009 Oct 01; 315(16):2847-55. PubMed ID: 19497323
    [Abstract] [Full Text] [Related]

  • 2. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ, Scollard DA, Reilly RM.
    J Nucl Med; 2012 Dec 01; 53(12):1943-50. PubMed ID: 23096164
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 4. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
    Blackburn E, Zona S, Murphy ML, Brown IR, Chan SK, Gullick WJ.
    Breast Cancer Res Treat; 2012 Jul 01; 134(1):53-9. PubMed ID: 22169894
    [Abstract] [Full Text] [Related]

  • 5. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
    Cancer Sci; 2007 Sep 01; 98(9):1498-503. PubMed ID: 17627612
    [Abstract] [Full Text] [Related]

  • 6. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Sep 01; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 7. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar 01; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 8. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM.
    Oncogene; 2003 Nov 06; 22(50):8178-86. PubMed ID: 14603258
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
    Campiglio M, Ali S, Knyazev PG, Ullrich A.
    J Cell Biochem; 1999 Jun 15; 73(4):522-32. PubMed ID: 10733345
    [Abstract] [Full Text] [Related]

  • 10. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH, Lin CC, Lin JK, Chen WJ.
    J Agric Food Chem; 2007 Jun 27; 55(13):5030-7. PubMed ID: 17539658
    [Abstract] [Full Text] [Related]

  • 11. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU, Wallasch C, Campiglio M, Issing W, Ullrich A.
    J Cell Physiol; 1997 Nov 27; 173(2):187-95. PubMed ID: 9365520
    [Abstract] [Full Text] [Related]

  • 12. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
    Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A.
    Clin Cancer Res; 2002 Oct 27; 8(10):3285-9. PubMed ID: 12374700
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
    Chen CH, Chernis GA, Hoang VQ, Landgraf R.
    Proc Natl Acad Sci U S A; 2003 Aug 05; 100(16):9226-31. PubMed ID: 12874383
    [Abstract] [Full Text] [Related]

  • 14. Forskolin increases neuregulin receptors in human Schwann cells without increasing receptor mRNA.
    Fregien NL, White LA, Bunge MB, Wood PM.
    Glia; 2005 Jan 01; 49(1):24-35. PubMed ID: 15390106
    [Abstract] [Full Text] [Related]

  • 15. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
    Nishiyama H, Soeda S, Watanabe T, Fujimori K.
    Fukushima J Med Sci; 2012 Jan 01; 58(1):22-32. PubMed ID: 22790889
    [Abstract] [Full Text] [Related]

  • 16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J, Lee J, Kim C, Choi J, Kim A.
    Tumour Biol; 2016 May 01; 37(5):5811-9. PubMed ID: 26581908
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
    Landgraf R, Pegram M, Slamon DJ, Eisenberg D.
    Biochemistry; 1998 Mar 03; 37(9):3220-8. PubMed ID: 9485477
    [Abstract] [Full Text] [Related]

  • 18. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
    Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC.
    Clin Cancer Res; 1999 Nov 03; 5(11):3653-60. PubMed ID: 10589783
    [Abstract] [Full Text] [Related]

  • 19. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
    Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K.
    Oncotarget; 2014 Dec 15; 5(23):11847-56. PubMed ID: 25474137
    [Abstract] [Full Text] [Related]

  • 20. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S, Han J, Shin I, Kil WH, Lee JE, Nam SJ.
    Exp Mol Med; 2012 Aug 31; 44(8):473-82. PubMed ID: 22627808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.